Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · August 08, 2019

PD-L1 Expression and Clinical Outcomes With Cabozantinib, Everolimus, and Sunitinib in Patients With Metastatic RCC

Clinical Cancer Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus and Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Clin. Cancer Res 2019 Aug 01;[EPub Ahead of Print], A Flaifel, W Xie, DA Braun, M Ficial, Z Bakouny, AH Nassar, RB Jennings, B Escudier, DJ George, RJ Motzer, MJ Morris, T Powles, E Wang, Y Huang, GJ Freeman, TK Choueiri, S Signoretti

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.


Further Reading